After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
Working to move beyond its core business of cystic fibrosis treatments, Vertex recently gained approval for Casgevy, a gene editing therapy for sickle cell disease and beta thalassemia.
A total of 46 listed biotech transactions worth more than $100 billion were announced across the industry last year, the highest since spending peaked in 2019.
Drugmakers have been focused on buying late-stage assets with larger revenue potential to replace older blockbuster drugs that have fallen out of favor.